Stephanie van Hoppe

37 ABCG2 & ABCB1 transport afatinib and restrict its oral availability and brain accumulation 24. Jonker, J.W., et al., The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med, 2005. 11(2): p. 127-9. 25. Zhang, Y., et al., PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed, 2010. 99(3): p. 306-14. 26. Goh, L.B., et al., Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol, 2002. 64(11): p. 1569-78. 27. Yabuki, N., et al., Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet, 2007. 173(1): p. 1-9. 28. Pesic, M., et al., Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother, 2006. 18(1): p. 66-73. 29. Khalifa, J., et al., Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted therapies. J Thorac Oncol, 2016. 30. Poller, B., et al., Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos, 2011. 39(5): p. 729-35. 31. Tang, S.C., et al., Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer, 2012. 130(1): p. 223-33. 32. Kort, A., et al., Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res, 2015. 102: p. 200-7. 33. Polli, J.W., et al., An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos, 2009. 37(2): p. 439-42. 34. Agarwal, S., et al., Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther, 2010. 334(1): p. 147-55. 35. Kodaira, H., et al., Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther, 2010. 333(3): p. 788-96. 36. Lagas, J.S., et al., Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res, 2009. 15(7): p. 2344-51. 37. Oostendorp, R.L., et al., The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs, 2009. 27(1): p. 31-40. 38. Kalvass, J.C. and G.M. Pollack, Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res, 2007. 24(2): p. 265-76. 39. Tang, S.C., et al., P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clin Cancer Res, 2014. 20(12): p. 3133-45. 40. Tang, S.C., et al., P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Mol Pharm, 2015. 12(10): p. 3714-23. 41. Schuler, M., et al., Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol, 2016. 27(3): p. 417-23. 42. Hochmair, M., S. Holzer, and O.C. Burghuber, Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs, 2016. 43. Hoffknecht, P., et al., Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol, 2015. 10(1): p. 156-63. 44. Clement, P.M., et al., Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol, 2016. 27(8): p. 1585-93.